CYNATA THERAPEUTICS LIMITED - Announcements

8.82%

15.5¢

Market Cap $35.02M

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and... Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.More

RCE'S BREAKTHROUGH

Recce Pharmaceuticals (ASX:RCE) accelerates commercialisation with positive Phase II results.

Announcements

Filter Results

All Price Sensitive Only

CYP	Proposed Issue of Securities		22/04/20	415.3KB	Share
CYP	Trading Halt	PRICE SENSITIVE	20/04/20	242.54KB	Share
CYP	Cynata MSCs beneficial in preclinical ARDS study	PRICE SENSITIVE	17/04/20	241.24KB	Share
CYP	Cynata provides guidance on planned clinical trials	PRICE SENSITIVE	01/04/20	195.85KB	Share
CYP	Market Update & Additional A$618k R&D Tax Refund	PRICE SENSITIVE	11/03/20	201.52KB	Share
CYP	Cynata Receives Japan Patent Notice of Allowance		10/03/20	192.12KB	Share
CYP	Canadian Patent Issued for CYP Unique Stem Cell Technology		03/03/20	182.01KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	20/02/20	680.83KB	Share
CYP	Notice of Allowance from Israel Patent Office	PRICE SENSITIVE	06/02/20	184.85KB	Share
CYP	Cynata Investor Presentation		31/01/20	1.65MB	Share
CYP	December 2019 Quarterly Report	PRICE SENSITIVE	30/01/20	394.94KB	Share
CYP	Cynata Receives UK Regulatory Approval for CLI Trial	PRICE SENSITIVE	14/01/20	197.59KB	Share
CYP	Cynata Receives $1.892m R&D Tax Incentive Refund	PRICE SENSITIVE	07/01/20	159.51KB	Share
CYP	Appendix 3Y-Dr Paul Wotton		16/12/19	25.68KB	Share
CYP	Corporate Presentation in Relation to Sepsis		09/12/19	1.48MB	Share
CYP	Cymerus MSCs Effective in Preclinical Model of Sepsis	PRICE SENSITIVE	05/12/19	171.52KB	Share
CYP	Results of Annual General Meeting		27/11/19	188.16KB	Share
CYP	Cynata Annual General Meeting Presentation		27/11/19	1.78MB	Share
CYP	Chairman's 2019 AGM Address		27/11/19	145.57KB	Share
CYP	CYP Files Application to Commence Phase 2 CLI Clinical Trial	PRICE SENSITIVE	25/11/19	195.33KB	Share
CYP	Appendix 3Y-Dr Paul Wotton		18/11/19	26.03KB	Share
CYP	Notification of Expiry of Unlisted Options		18/11/19	156.49KB	Share
CYP	Appendix 3Y-Mr Peter Webse		11/11/19	26.72KB	Share
CYP	Appendix 3Y-Dr Ross Macdonald		11/11/19	26.5KB	Share
CYP	Appendix 3Y-Dr Paul Wotton		11/11/19	26.75KB	Share
CYP	Cleansing Notice		11/11/19	104.21KB	Share
CYP	Appendix 3B-Exercise of Options		11/11/19	187.34KB	Share
CYP	Cynata Corporate Presentation		30/10/19	1.63MB	Share
CYP	Cynata Awarded Grant for Coronary Artery Disease Study	PRICE SENSITIVE	28/10/19	186.55KB	Share
CYP	Notice of Allowance from CIPO for Patent Application	PRICE SENSITIVE	25/10/19	185.68KB	Share
CYP	Annual Report to shareholders		24/10/19	1.25MB	Share
CYP	Notice of Annual General Meeting/Proxy Form		24/10/19	1.04MB	Share
CYP	September 2019 Quarterly Report	PRICE SENSITIVE	24/10/19	345.42KB	Share
CYP	Cynata & Sumitomo Withdraw from Acquisition Discussions	PRICE SENSITIVE	17/10/19	177.78KB	Share
CYP	Receipt of notice under section 249N of the Corporations Act		14/10/19	2.49MB	Share
CYP	CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial	PRICE SENSITIVE	03/10/19	210.02KB	Share
CYP	Notification of 2019 Annual General Meeting Date		27/09/19	160.59KB	Share
CYP	Cynata Receives US$3 million Fujifilm License Fee	PRICE SENSITIVE	26/09/19	162.19KB	Share
CYP	Cleansing Notice		18/09/19	102.27KB	Share
CYP	Appendix 3B-Exercise of Options		18/09/19	187.5KB	Share
CYP	Fujifilm Exercises License Option in GvHD	PRICE SENSITIVE	17/09/19	209.92KB	Share
CYP	Trading Halt	PRICE SENSITIVE	13/09/19	186.48KB	Share
CYP	Expiry of Voluntary Escrow Arrangement		09/09/19	184.51KB	Share
CYP	Cynata transplant rejection study accepted for publication		04/09/19	202.21KB	Share
CYP	Cleansing Notice		03/09/19	102.5KB	Share
CYP	Appendix 3B-Exercise of Options		03/09/19	187.38KB	Share
CYP	Cleansing Notice		27/08/19	102.25KB	Share
CYP	Appendix 3B-Exercise of Options		27/08/19	187.21KB	Share
CYP	Appendix 4G		23/08/19	221.07KB	Share
CYP	Appendix 4E & Annual Report	PRICE SENSITIVE	23/08/19	1.26MB	Share
CYP	Cleansing Notice		15/08/19	102.25KB	Share
CYP	Appendix 3B-Exercise of Options		15/08/19	188.97KB	Share
CYP	Update on Discussions with Sumitomo and Fujifilm	PRICE SENSITIVE	15/08/19	182.65KB	Share
CYP	Cleansing Notice		02/08/19	102.54KB	Share
CYP	Appendix 3B-Exercise of Options		02/08/19	190.6KB	Share
CYP	Response to ASX Aware Query	PRICE SENSITIVE	24/07/19	785.23KB	Share
CYP	Response to ASX Price and Volume Query	PRICE SENSITIVE	19/07/19	537.26KB	Share
CYP	Cynata confirms receipt of indicative non-binding proposal	PRICE SENSITIVE	19/07/19	184.58KB	Share
CYP	Trading Halt	PRICE SENSITIVE	17/07/19	214.44KB	Share
CYP	June 2019 Quarterly Report	PRICE SENSITIVE	04/07/19	393.87KB	Share
CYP	Cynata's Cymerus Technology Featured in ISCT Presentations		30/05/19	217.24KB	Share
CYP	Appendix 3Z-Dr John Chiplin		20/05/19	27.07KB	Share
CYP	Appendix 3Y-Dr Geoff Brooke		20/05/19	29.65KB	Share
CYP	Appendix 3B		20/05/19	190.39KB	Share
CYP	Cynata Strengthens Board & Executive Management Team	PRICE SENSITIVE	20/05/19	205.83KB	Share
CYP	Appendix 3Y-Dr John Chiplin		07/05/19	24.83KB	Share
CYP	Cleansing Notice		07/05/19	102.05KB	Share
CYP	Appendix 3B - Exercise of Options		07/05/19	188.67KB	Share
CYP	CYP Progresses Start-Up Activities for Clinical Trial in CLI		06/05/19	175.91KB	Share
CYP	March 2019 Quarterly Report	PRICE SENSITIVE	26/04/19	384.45KB	Share
CYP	European Patent Isued to Cynata Therapeutics		04/04/19	201.83KB	Share
CYP	Extension of FUJIFILM Licence Option in GvHD		21/03/19	194.68KB	Share
CYP	Cleansing Notice		21/03/19	102.42KB	Share
CYP	Cynata Extends FUJIFILM Licence Option in GvHD	PRICE SENSITIVE	21/03/19	196.96KB	Share
CYP	Appendix 3B-Exercise of Options		20/03/19	189.25KB	Share
CYP	Trading Halt	PRICE SENSITIVE	19/03/19	329.31KB	Share
CYP	Cleansing Notice		13/03/19	102.58KB	Share
CYP	Appendix 3B-Exercise of Options		13/03/19	189.3KB	Share
CYP	Cynata Receives Favourable Advice on Planned CLI Trial	PRICE SENSITIVE	12/03/19	171.99KB	Share
CYP	Joint Study of Cynata MSCs receives VMRAF Funding		11/03/19	164.04KB	Share
CYP	Positive Pre-Clinical Coronary Artery Disease Data for CYP		04/03/19	195.77KB	Share
CYP	Appendix 4D & Half-Year Financial Statements	PRICE SENSITIVE	27/02/19	957.08KB	Share
CYP	Further Cynata Asthma Study Published		25/02/19	230.67KB	Share
CYP	Cleansing Notice		22/02/19	103.09KB	Share
CYP	Appendix 3B-Exercise of Options		22/02/19	189.91KB	Share
CYP	Cleansing Notice		18/02/19	102.56KB	Share
CYP	Appendix 3B-Exercise of Options		18/02/19	189KB	Share
CYP	Appendix 3Y-Dr John Chiplin		11/02/19	24.81KB	Share
CYP	Cleansing Notice		11/02/19	102.78KB	Share
CYP	Appendix 3B-Exercise of Options		11/02/19	191.06KB	Share
CYP	Study of CYP-001 Published in Leading Peer Review Journal		07/02/19	225.94KB	Share
CYP	Cleansing Notice		04/02/19	102.57KB	Share
CYP	Appendix 3B-Exercise of Options		04/02/19	190.07KB	Share
CYP	December 2018 Quarterly Report	PRICE SENSITIVE	29/01/19	350.71KB	Share
CYP	Clinical trial results to be presented at major symposium		29/01/19	174.61KB	Share
CYP	CYP Receives Notice of Acceptance from Aust Patent Office	PRICE SENSITIVE	07/01/19	186.08KB	Share
CYP	End of Year Newsletter		20/12/18	346.68KB	Share
CYP	Cynata Completes Clinical Study Report in GvHD	PRICE SENSITIVE	18/12/18	181.76KB	Share
CYP	NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs	PRICE SENSITIVE	13/12/18	211.91KB	Share
CYP	Cynata Receives $1.3m R&D Tax Incentive Refund	PRICE SENSITIVE	19/11/18	163.89KB	Share

CYP Proposed Issue of Securities
22/04/20		415.3KB	Share
CYP Trading Halt
20/04/20	PRICE SENSITIVE	242.54KB	Share
CYP Cynata MSCs beneficial in preclinical ARDS study
17/04/20	PRICE SENSITIVE	241.24KB	Share
CYP Cynata provides guidance on planned clinical trials
01/04/20	PRICE SENSITIVE	195.85KB	Share
CYP Market Update & Additional A$618k R&D Tax Refund
11/03/20	PRICE SENSITIVE	201.52KB	Share
CYP Cynata Receives Japan Patent Notice of Allowance
10/03/20		192.12KB	Share
CYP Canadian Patent Issued for CYP Unique Stem Cell Technology
03/03/20		182.01KB	Share
CYP Appendix 4D & Half-Year Financial Statements
20/02/20	PRICE SENSITIVE	680.83KB	Share
CYP Notice of Allowance from Israel Patent Office
06/02/20	PRICE SENSITIVE	184.85KB	Share
CYP Cynata Investor Presentation
31/01/20		1.65MB	Share
CYP December 2019 Quarterly Report
30/01/20	PRICE SENSITIVE	394.94KB	Share
CYP Cynata Receives UK Regulatory Approval for CLI Trial
14/01/20	PRICE SENSITIVE	197.59KB	Share
CYP Cynata Receives $1.892m R&D Tax Incentive Refund
07/01/20	PRICE SENSITIVE	159.51KB	Share
CYP Appendix 3Y-Dr Paul Wotton
16/12/19		25.68KB	Share
CYP Corporate Presentation in Relation to Sepsis
09/12/19		1.48MB	Share
CYP Cymerus MSCs Effective in Preclinical Model of Sepsis
05/12/19	PRICE SENSITIVE	171.52KB	Share
CYP Results of Annual General Meeting
27/11/19		188.16KB	Share
CYP Cynata Annual General Meeting Presentation
27/11/19		1.78MB	Share
CYP Chairman's 2019 AGM Address
27/11/19		145.57KB	Share
CYP CYP Files Application to Commence Phase 2 CLI Clinical Trial
25/11/19	PRICE SENSITIVE	195.33KB	Share
CYP Appendix 3Y-Dr Paul Wotton
18/11/19		26.03KB	Share
CYP Notification of Expiry of Unlisted Options
18/11/19		156.49KB	Share
CYP Appendix 3Y-Mr Peter Webse
11/11/19		26.72KB	Share
CYP Appendix 3Y-Dr Ross Macdonald
11/11/19		26.5KB	Share
CYP Appendix 3Y-Dr Paul Wotton
11/11/19		26.75KB	Share
CYP Cleansing Notice
11/11/19		104.21KB	Share
CYP Appendix 3B-Exercise of Options
11/11/19		187.34KB	Share
CYP Cynata Corporate Presentation
30/10/19		1.63MB	Share
CYP Cynata Awarded Grant for Coronary Artery Disease Study
28/10/19	PRICE SENSITIVE	186.55KB	Share
CYP Notice of Allowance from CIPO for Patent Application
25/10/19	PRICE SENSITIVE	185.68KB	Share
CYP Annual Report to shareholders
24/10/19		1.25MB	Share
CYP Notice of Annual General Meeting/Proxy Form
24/10/19		1.04MB	Share
CYP September 2019 Quarterly Report
24/10/19	PRICE SENSITIVE	345.42KB	Share
CYP Cynata & Sumitomo Withdraw from Acquisition Discussions
17/10/19	PRICE SENSITIVE	177.78KB	Share
CYP Receipt of notice under section 249N of the Corporations Act
14/10/19		2.49MB	Share
CYP CYP Advances Towards Osteoarthritis Phase 2 Clinical Trial
03/10/19	PRICE SENSITIVE	210.02KB	Share
CYP Notification of 2019 Annual General Meeting Date
27/09/19		160.59KB	Share
CYP Cynata Receives US$3 million Fujifilm License Fee
26/09/19	PRICE SENSITIVE	162.19KB	Share
CYP Cleansing Notice
18/09/19		102.27KB	Share
CYP Appendix 3B-Exercise of Options
18/09/19		187.5KB	Share
CYP Fujifilm Exercises License Option in GvHD
17/09/19	PRICE SENSITIVE	209.92KB	Share
CYP Trading Halt
13/09/19	PRICE SENSITIVE	186.48KB	Share
CYP Expiry of Voluntary Escrow Arrangement
09/09/19		184.51KB	Share
CYP Cynata transplant rejection study accepted for publication
04/09/19		202.21KB	Share
CYP Cleansing Notice
03/09/19		102.5KB	Share
CYP Appendix 3B-Exercise of Options
03/09/19		187.38KB	Share
CYP Cleansing Notice
27/08/19		102.25KB	Share
CYP Appendix 3B-Exercise of Options
27/08/19		187.21KB	Share
CYP Appendix 4G
23/08/19		221.07KB	Share
CYP Appendix 4E & Annual Report
23/08/19	PRICE SENSITIVE	1.26MB	Share
CYP Cleansing Notice
15/08/19		102.25KB	Share
CYP Appendix 3B-Exercise of Options
15/08/19		188.97KB	Share
CYP Update on Discussions with Sumitomo and Fujifilm
15/08/19	PRICE SENSITIVE	182.65KB	Share
CYP Cleansing Notice
02/08/19		102.54KB	Share
CYP Appendix 3B-Exercise of Options
02/08/19		190.6KB	Share
CYP Response to ASX Aware Query
24/07/19	PRICE SENSITIVE	785.23KB	Share
CYP Response to ASX Price and Volume Query
19/07/19	PRICE SENSITIVE	537.26KB	Share
CYP Cynata confirms receipt of indicative non-binding proposal
19/07/19	PRICE SENSITIVE	184.58KB	Share
CYP Trading Halt
17/07/19	PRICE SENSITIVE	214.44KB	Share
CYP June 2019 Quarterly Report
04/07/19	PRICE SENSITIVE	393.87KB	Share
CYP Cynata's Cymerus Technology Featured in ISCT Presentations
30/05/19		217.24KB	Share
CYP Appendix 3Z-Dr John Chiplin
20/05/19		27.07KB	Share
CYP Appendix 3Y-Dr Geoff Brooke
20/05/19		29.65KB	Share
CYP Appendix 3B
20/05/19		190.39KB	Share
CYP Cynata Strengthens Board & Executive Management Team
20/05/19	PRICE SENSITIVE	205.83KB	Share
CYP Appendix 3Y-Dr John Chiplin
07/05/19		24.83KB	Share
CYP Cleansing Notice
07/05/19		102.05KB	Share
CYP Appendix 3B - Exercise of Options
07/05/19		188.67KB	Share
CYP CYP Progresses Start-Up Activities for Clinical Trial in CLI
06/05/19		175.91KB	Share
CYP March 2019 Quarterly Report
26/04/19	PRICE SENSITIVE	384.45KB	Share
CYP European Patent Isued to Cynata Therapeutics
04/04/19		201.83KB	Share
CYP Extension of FUJIFILM Licence Option in GvHD
21/03/19		194.68KB	Share
CYP Cleansing Notice
21/03/19		102.42KB	Share
CYP Cynata Extends FUJIFILM Licence Option in GvHD
21/03/19	PRICE SENSITIVE	196.96KB	Share
CYP Appendix 3B-Exercise of Options
20/03/19		189.25KB	Share
CYP Trading Halt
19/03/19	PRICE SENSITIVE	329.31KB	Share
CYP Cleansing Notice
13/03/19		102.58KB	Share
CYP Appendix 3B-Exercise of Options
13/03/19		189.3KB	Share
CYP Cynata Receives Favourable Advice on Planned CLI Trial
12/03/19	PRICE SENSITIVE	171.99KB	Share
CYP Joint Study of Cynata MSCs receives VMRAF Funding
11/03/19		164.04KB	Share
CYP Positive Pre-Clinical Coronary Artery Disease Data for CYP
04/03/19		195.77KB	Share
CYP Appendix 4D & Half-Year Financial Statements
27/02/19	PRICE SENSITIVE	957.08KB	Share
CYP Further Cynata Asthma Study Published
25/02/19		230.67KB	Share
CYP Cleansing Notice
22/02/19		103.09KB	Share
CYP Appendix 3B-Exercise of Options
22/02/19		189.91KB	Share
CYP Cleansing Notice
18/02/19		102.56KB	Share
CYP Appendix 3B-Exercise of Options
18/02/19		189KB	Share
CYP Appendix 3Y-Dr John Chiplin
11/02/19		24.81KB	Share
CYP Cleansing Notice
11/02/19		102.78KB	Share
CYP Appendix 3B-Exercise of Options
11/02/19		191.06KB	Share
CYP Study of CYP-001 Published in Leading Peer Review Journal
07/02/19		225.94KB	Share
CYP Cleansing Notice
04/02/19		102.57KB	Share
CYP Appendix 3B-Exercise of Options
04/02/19		190.07KB	Share
CYP December 2018 Quarterly Report
29/01/19	PRICE SENSITIVE	350.71KB	Share
CYP Clinical trial results to be presented at major symposium
29/01/19		174.61KB	Share
CYP CYP Receives Notice of Acceptance from Aust Patent Office
07/01/19	PRICE SENSITIVE	186.08KB	Share
CYP End of Year Newsletter
20/12/18		346.68KB	Share
CYP Cynata Completes Clinical Study Report in GvHD
18/12/18	PRICE SENSITIVE	181.76KB	Share
CYP NHMRC Funding for Osteoarthritis Trial Using Cymerus MSCs
13/12/18	PRICE SENSITIVE	211.91KB	Share
CYP Cynata Receives $1.3m R&D Tax Incentive Refund
19/11/18	PRICE SENSITIVE	163.89KB	Share

REFRESH

First 2 3 4 5 6

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 15.5¢		Change -0.015(8.82%)		Mkt cap ! $35.02M

Open	High	Low	Value	Volume
17.0¢	17.0¢	15.5¢	$35.01K	213.1K

Buyers (Bids)

No.	Vol.	Price($)
4	201289	15.5¢

Sellers (Offers)

Price($)	Vol.	No.
16.5¢	14675	1

View Market Depth

No.	Vol.	Price($)
4	201289	0.155
7	323545	0.150
4	81775	0.145
5	315005	0.140
1	5000	0.130

Price($)	Vol.	No.
0.165	14675	1
0.170	26942	1
0.175	54733	2
0.180	165059	2
0.185	25916	1

Last trade - 16.10pm 31/07/2025 (20 minute delay)


Last 15.5¢		Change -0.015 ( 8.82 %)
Open	High	Low	Volume
17.3¢	17.3¢	15.5¢	186445
Last updated 15.55pm 31/07/2025 ?

CYP (ASX) Chart

CYNATA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

A new NASDAQ listing for a key player in the global critical minerals space

Top Stories